If someone has run Reading a supplementary appendix properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
[2026 update] Reading a supplementary appendix and finding the interesting part
Reading the supplementary appendix is where most of the real information is, and it is where almost nobody goes. The baseline table alone answers half the generalisability questions asked here.
Where I part company with post #22, and it is a narrow parting.
A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.
Flagging that the sources on this are thinner than the confidence in the thread suggests.
Practical answer on Reading a supplementary appendix, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
This follows post #29 rather than contradicting it.
I would rather this thread reach "we do not know" about Reading a supplementary appendix than reach a confident answer that nobody can support when asked.
I disagree with the framing of Reading a supplementary appendix above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Read the full topic (45 posts)
This topic was referenced in
- Comparators chosen for regulatory reasons rather than clinical onesEvidence › Trials · 2 replies
- Run-in periods and the population they select — the long versionEvidence › Trials · 2 replies
- Follow-up: Open-label extensions: what survives and what does notEvidence › Trials · 26 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. I have spent a fortnight trying to pin open-label extensions down…
|
4 | 22k | 3mo | |
|
[2026 update] Composite endpoints and the component doing the work
On the subject in the title: Composite endpoints and the component doing the work Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-4 ( Lancet , 2021) and…
|
+76 | 87 | 994 | 3mo |
|
Trial registration and comparing the protocol with the paper
Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…
|
+38 | 44 | 4.8k | 10mo |
|
Follow-up: Open-label extensions: what survives and what does not
Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin Open-label extensions down and I want to set…
|
+22 | 26 | 397 | 16mo |
|
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…
|
2 | 6.6k | 10h |
Related topics — sharing the tags estimand, intention to treat, open label
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
|
+80 | 91 | 10k | 11mo |
|
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. TRIUMPH keeps being re-asked here and I think…
|
+4 | 8 | 142 | 6h |
|
Hepatic effects of glucagon receptor agonism: the mechanistic worry
Posting this under the heading it deserves: Hepatic effects of glucagon receptor agonism: the mechanistic worry Everything below is what sits behind that. Something about hepatic effects of glucagon receptor…
|
+51 | 56 | 700 | 22mo |
|
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. A narrow question about semaglutide…
|
3 | 28k | 6mo | |
|
Trial registration and comparing the protocol with the paper
Trial registration and comparing the protocol with the paper — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin trial registration down and I want to…
|
+38 | 44 | 4.8k | 10mo |